# EDGAR Filing Document

**Accession Number:** 0001426156
**File Stem:** 0001019056-26-000067
**Filing Date:** 2026-3
**Character Count:** 15682
**Document Hash:** 3e8eed7f4ede1ebc18284e6d44d9b05a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001019056-26-000067.hdr.sgml**: 20260330

**ACCESSION NUMBER**: 0001019056-26-000067

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260330

**DATE AS OF CHANGE**: 20260330

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evotec SE
- **CENTRAL INDEX KEY:** 0001412558
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-84013
- **FILM NUMBER:** 26816311

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 22419
- **BUSINESS PHONE:** 49-40-560-810

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 22419

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Evotec AG
- **DATE OF NAME CHANGE:** 20070917
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAK Capital Fund LP
- **CENTRAL INDEX KEY:** 0001426156

**ORGANIZATION NAME:**
- **EIN:** 980416772
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 590 MADISON AVENUE
- **STREET 2:** 31ST FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-486-3211

**MAIL ADDRESS:**
- **STREET 1:** 590 MADISON AVENUE
- **STREET 2:** 31ST FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

## Ex-1

**EXHIBIT 1**

**Transactions in the Securities of the Issuer During the Past 60 Days**

The following purchases were made on the open market, unless otherwise noted.

---

| | | |
|:---|:---|:---|
| **Date** | **Number of<br> Shares** | **Price Per <br> Share (EUR)** |
| 1/29/2026 | 300000 | 6.2787 |
| 1/30/2026 | 116434 | 6.1607 |
| 2/6/2026 | 56108 | 6.0690 |
| 2/9/2026 | 159947 | 6.1187 |
| 3/11/2026 | 250000 | 4.4192 |
| 3/12/2026 | 125000 | 4.3418 |
| 3/13/2026 | 250000 | 4.1544 |
| 3/16/2026 | 105699 | 4.1858 |
| 3/17/2026 | 33610 | 4.3043 |
| 3/18/2026 | 120000 | 4.3572 |
| 3/19/2026 | 140407 | 4.2906 |
| 3/20/2026 | 220000 | 4.3185 |
| 3/23/2026 | 36719 | 4.0685 |
| 3/25/2026 | 1233 | 4.3483 |

---

## Exhibit 99.1

**Exhibit 99.1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Ordinary Shares, no par value per share, of EVOTEC SE. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.

---

| | |
|:---|:---|
| **MAK Capital Fund LP** | **MAK Capital Fund LP** |
| By: | /s/ Michael A. Kaufman |
|  | Michael A. Kaufman, Managing Member |
| Date: | 03/30/2026 |
| **MAK CAPITAL ONE LLC** | **MAK CAPITAL ONE LLC** |
| By: | /s/ Michael A. Kaufman |
|  | Michael A. Kaufman, Managing Member |
| Date: | 03/30/2026 |
| **Michael A. Kaufman** | **Michael A. Kaufman** |
| By: | /s/ Michael A. Kaufman |
|  | Michael A. Kaufman |
| Date: | 03/30/2026 |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Evotec SE**

*(Name of Issuer)*

**Ordinary Shares, no par value per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**David N. Smith, Jr.**<br>590 Madison Avenue<br>31st Floor<br>New York NY 10022<br>212-486-3211

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/30/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**MAK Capital Fund LP** | Name of reporting person<br>**MAK Capital Fund LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D0** | Citizenship or place of organization<br>**D0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12503512.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12503512.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12503512.00** | Aggregate amount beneficially owned by each reporting person<br>**12503512.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.0%** | Percent of class represented by amount in Row (11)<br>**7.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** For Item 13:

The calculation is based upon 177,877,782 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of March 30, 2026, as reported by the Issuer on its website.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**MAK Capital One L.L.C.** | Name of reporting person<br>**MAK Capital One L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12503512.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12503512.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12503512.00** | Aggregate amount beneficially owned by each reporting person<br>**12503512.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.0%** | Percent of class represented by amount in Row (11)<br>**7.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** For item 13:

The calculation is based upon 177,877,782 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of March 30, 2026, as reported by the Issuer on its website.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Michael A. Kaufman** | Name of reporting person<br>**Michael A. Kaufman** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12503512.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12503512.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12503512.00** | Aggregate amount beneficially owned by each reporting person<br>**12503512.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.0%** | Percent of class represented by amount in Row (11)<br>**7.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** For item 13:

The calculation is based upon 177,877,782 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of March 30, 2026, as reported by the Issuer on its website.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, no par value per share

**(b) Name of Issuer:**
Evotec SE

**(c) Address of Issuer's Principal Executive Offices:**
Essener Bogen 7, Hamburg, 2M, 22419

**Item 4. Purpose of Transaction**

On March 30, 2026 representatives of MAK had a telephonic conversation with Prof. Dr. Iris Low-Friedrich, the Chairwoman of the Supervisory Board of the Issuer. During the call, MAK's representatives expressed their views regarding potential strategic and governance improvements at the Issuer designed to enhance long-term shareholder value. MAK requested that the Issuer consider nominating Dr. Wolfgang Hofmann to the Issuer's Supervisory Board.  MAK also requested that the Issuer consider immediate steps to IPO and subsequently spin out the Just-Evotec Biologics US subsidiary.  No agreement or understanding was reached with respect to these matters, and the Issuer has not committed to any specific actions.

MAK believes that changes to Evotec's current strategy and governance are warranted.  MAK intends to continue to actively engage with the Management and Supervisory Boards regarding such matters and may from time to time consider various alternatives to enhance shareholder value.

No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The aggregate percentage of Shares reported owned by each person named herein is based upon 177,877,782 Shares (including Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of March 30, 2026, as reported by the Issuer on its website.

As of the date hereof, MAK Fund beneficially owns directly  12,503,512 Shares, representing approximately 7.0% of the outstanding Shares.

MAK Capital, as the investment manager of MAK Fund, may be deemed to beneficially own the  12,503,512 Shares beneficially owned directly by MAK Fund, representing approximately 7.0% of the outstanding Shares. Mr. Kaufman, as the Managing Member of MAK Capital, may be deemed to beneficially own the  12,503,512 Shares beneficially owned directly by MAK Fund, representing approximately 7.0% of the outstanding Shares.

The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

**(b)**
Each of MAK Fund, MAK Capital and Mr. Kaufman may be deemed to share the power to vote and dispose of the Shares beneficially owned directly by MAK Fund.

**(c)**
The transactions in securities of the Issuer by the Reporting Persons during the past 60 days are set forth in Exhibit 1 and are incorporated herein by reference. All of such transactions were effected in the open market unless otherwise noted therein.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

On March 30, 2026, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** MAK Capital Fund LP

**Signature:** /s/ Michael A. Kaufman

**Name/Title:** Managing Member

**Date:** 03/30/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** MAK Capital One L.L.C.

**Signature:** /s/ Michael A. Kaufman

**Name/Title:** Managing Member

**Date:** 03/30/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Michael A. Kaufman

**Signature:** /s/ Michael A. Kaufman

**Name/Title:** Michael A. Kaufman

**Date:** 03/30/2026